This product is indicated for the control of hyperphosphatemia in CKD adults on dialysis.
This product is indicated for the treatment of chorea in Huntington's disease. Chorea in Huntington's disease is a rare autosomal dominant neurodegenerative disorder affecting the central nervous system (included in the 2018 China's First List of Rare Diseases). Symptoms include involuntary dance-like movements, cognitive impairment and mental disorders. Tetrabenazine is the world's first drug used to treat chorea in Huntington's disease.
Adjuvant therapy to levodopa/benserazide or levodopa/carbidopa for the treatment of Parkinson's disease and wearing-off phenomenon (symptom fluctuation) not adequately controlled by these standards of care
< 1 >